IS7431A - Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða - Google Patents
Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíðaInfo
- Publication number
- IS7431A IS7431A IS7431A IS7431A IS7431A IS 7431 A IS7431 A IS 7431A IS 7431 A IS7431 A IS 7431A IS 7431 A IS7431 A IS 7431A IS 7431 A IS7431 A IS 7431A
- Authority
- IS
- Iceland
- Prior art keywords
- biologically active
- conjugates
- cytotoxic agents
- drugs
- active peptides
- Prior art date
Links
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 239000002254 cytotoxic agent Substances 0.000 title abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36083102P | 2002-03-01 | 2002-03-01 | |
| PCT/US2003/006657 WO2003074551A2 (en) | 2002-03-01 | 2003-03-03 | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7431A true IS7431A (is) | 2004-08-31 |
Family
ID=27789031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7431A IS7431A (is) | 2002-03-01 | 2004-08-31 | Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7771727B2 (is) |
| EP (1) | EP1487493B1 (is) |
| JP (1) | JP4477881B2 (is) |
| KR (1) | KR101003622B1 (is) |
| CN (2) | CN1649625A (is) |
| AT (1) | ATE455561T1 (is) |
| AU (1) | AU2003220011B2 (is) |
| BR (1) | BR0308090A (is) |
| CA (1) | CA2476182A1 (is) |
| CO (1) | CO5611160A2 (is) |
| DE (1) | DE60331049D1 (is) |
| DK (1) | DK1487493T3 (is) |
| ES (1) | ES2339934T3 (is) |
| IL (1) | IL163573A0 (is) |
| IS (1) | IS7431A (is) |
| MX (1) | MXPA04008419A (is) |
| NO (1) | NO20044039L (is) |
| NZ (1) | NZ534719A (is) |
| PL (1) | PL373567A1 (is) |
| WO (1) | WO2003074551A2 (is) |
| ZA (1) | ZA200406614B (is) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| CN1761485B (zh) * | 2003-03-20 | 2010-04-28 | 日本化药株式会社 | 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂 |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| CN101791409A (zh) * | 2003-04-22 | 2010-08-04 | 研究及应用科学协会股份有限公司 | 肽载体 |
| US20060281897A1 (en) * | 2003-08-22 | 2006-12-14 | Andre Trouet | Potentialization of the activation of high molecular weight prodrugs |
| US9011880B2 (en) | 2003-10-21 | 2015-04-21 | Igf Oncology, Llc | Compounds and methods for treating cancer |
| CA2542834C (en) | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
| JP4820758B2 (ja) | 2004-09-22 | 2011-11-24 | 日本化薬株式会社 | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 |
| WO2006047214A2 (en) | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
| KR100897915B1 (ko) * | 2004-11-03 | 2009-05-18 | 포휴먼텍(주) | 경피전달을 위한 약제 조성물 |
| ATE535529T1 (de) | 2005-08-09 | 2011-12-15 | Millennium Pharm Inc | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| RU2447095C2 (ru) * | 2006-05-18 | 2012-04-10 | Ниппон Каяку Кабусики Кайся | Высокомолекулярный конъюгат подофиллотоксинов |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| SI2049664T1 (sl) | 2006-08-11 | 2012-04-30 | Prosensa Technologies Bv | Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev |
| JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
| CA2693742A1 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| WO2009008727A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| JP5349318B2 (ja) | 2007-09-28 | 2013-11-20 | 日本化薬株式会社 | ステロイド類の高分子結合体 |
| ES2639852T3 (es) | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| WO2009099326A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
| JP5366940B2 (ja) | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN101439182B (zh) * | 2008-12-18 | 2012-02-01 | 北京大学 | 一种生长抑素受体介导的肿瘤靶向药物组合物 |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| EP2421971B1 (en) | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| JP5544357B2 (ja) | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011078672A1 (en) | 2009-12-24 | 2011-06-30 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| KR20140024833A (ko) | 2010-11-17 | 2014-03-03 | 니폰 가야꾸 가부시끼가이샤 | 신규한 시티딘계 대사길항제의 고분자 유도체 |
| WO2012097333A2 (en) | 2011-01-14 | 2012-07-19 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
| WO2012112792A2 (en) | 2011-02-17 | 2012-08-23 | The Administrators Of The Tulane Educational Fund | Multicomponent compositions and their uses |
| CN103874722B (zh) | 2011-09-11 | 2016-06-29 | 日本化药株式会社 | 嵌段共聚物的制造方法 |
| NZ627896A (en) | 2012-01-27 | 2016-11-25 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| US9056910B2 (en) | 2012-05-01 | 2015-06-16 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| JP6847388B2 (ja) * | 2013-03-15 | 2021-03-31 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 生物活性分子、そのコンジュゲート、及び治療用途 |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| CA2936675C (en) | 2014-01-12 | 2023-06-27 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| CN105198966B (zh) * | 2014-06-26 | 2019-06-21 | 中国人民解放军军事医学科学院毒物药物研究所 | GnRH类似物-细胞毒分子缀合物、其制备方法及用途 |
| MX379365B (es) | 2014-06-30 | 2025-03-11 | Tarveda Therapeutics Inc | Conjugados y partículas direccionados y formulaciones de estos. |
| US11633487B2 (en) * | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| CN113912705B (zh) * | 2015-07-27 | 2023-12-22 | 上海贺普药业股份有限公司 | 一种肿瘤抑制肽 |
| CN113201048B (zh) | 2015-08-05 | 2022-10-04 | 陕西麦科奥特科技有限公司 | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 |
| CN106466485B (zh) * | 2015-08-11 | 2021-05-04 | 同宜医药（苏州）有限公司 | 一种具有细胞内吞介导功能的靶向配体-药物偶联体 |
| US11160871B2 (en) | 2015-10-28 | 2021-11-02 | Tarveda Therapeutics, Inc. | SSTR-targeted conjugates and particles and formulations thereof |
| CN109311910B (zh) | 2016-03-24 | 2022-02-01 | 杜兰教育基金委员会 | 他克莫司偶联物、其组合物、及其用途 |
| JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール．ピー．シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
| CN106492226A (zh) * | 2016-10-13 | 2017-03-15 | 武汉大学苏州研究院 | 肿瘤靶向性多肽—蒽环类衍生物 |
| CN117442747A (zh) | 2017-05-21 | 2024-01-26 | Igf肿瘤公司 | 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物 |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| AU2018321825A1 (en) * | 2017-08-19 | 2020-03-05 | Ohio State Innovation Foundation | Novel peptide-based cancer imaging agents |
| CN110357947B (zh) * | 2019-03-08 | 2023-05-26 | 南京恒远科技开发有限公司 | 一种combretastatin A4衍生物 |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| RU2727924C1 (ru) * | 2019-08-20 | 2020-07-27 | Открытое акционерное общество "Всероссийский научный центр молекулярной диагностики и лечения" (ОАО "ВНЦМДЛ") | Высокоэффективный способ получения лекарственной формы адресного действия для терапии злокачественных новообразований |
| CN117377495A (zh) * | 2021-06-09 | 2024-01-09 | 克林提克斯医药股份有限公司 | 非肽靶向治疗剂及其用途 |
| WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
| KR102821945B1 (ko) * | 2022-12-02 | 2025-06-17 | 성균관대학교산학협력단 | 광화학적 전환 가능한 펩티드-소분자 복합체 |
| TW202440164A (zh) | 2022-12-13 | 2024-10-16 | 美商克林提克斯醫藥股份有限公司 | 生長抑素亞型-2受體（sst2r）靶向治療劑及其用途 |
| CN118252943B (zh) * | 2023-10-25 | 2024-09-20 | 常州市智态生创科技有限公司 | 一种短肽偶联药物及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663306A (en) * | 1984-08-09 | 1997-09-02 | Chiron Corporation | Method of conjugating an activated ester to an amine-containing biological material |
| US4904642A (en) * | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4812590A (en) * | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
| US5073541A (en) | 1987-11-18 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Treatment of small cell lung cancer with somatostatin analogs |
| US5753627A (en) * | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| US5633263A (en) * | 1989-04-26 | 1997-05-27 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
| DK0436005T3 (da) | 1989-07-20 | 1995-07-03 | Sandoz Ltd | Mærkede polypeptidderivater |
| US5443815A (en) * | 1991-11-27 | 1995-08-22 | Diatech, Inc. | Technetium-99m labeled peptides for imaging |
| US5411943A (en) * | 1992-02-25 | 1995-05-02 | Biomeasure, Inc. | Hepatoma treatment with somatostatin analogs |
| US5620675A (en) * | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| US5597894A (en) * | 1995-06-05 | 1997-01-28 | The Louisiana State University Medical Center Foundation | Multi-tyrosinated somatostatin analogs |
| US5770687A (en) * | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
| US6051554A (en) * | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US5708135A (en) * | 1995-09-29 | 1998-01-13 | Biomeasure Incorporated | Cyclic peptide analogs of somatostatin |
| US5750499A (en) * | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| US5843903A (en) | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| US6156725A (en) * | 1996-08-16 | 2000-12-05 | National Institute Of Immunology | Drug for the treatment of cancer |
| US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
| EP0977579B1 (en) | 1997-04-22 | 2009-03-11 | Curator Of The University Of Missouri | Gastrin receptor-avid peptide conjugates |
| US6465613B1 (en) * | 1998-11-19 | 2002-10-15 | Tulane University | Hydrophilic somatostatin analogs |
| AU1607501A (en) | 1999-11-15 | 2001-05-30 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| AU4267700A (en) * | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
| US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| CN1589151A (zh) * | 2001-09-21 | 2005-03-02 | 图兰恩教育基金管理人 | 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途 |
-
2003
- 2003-03-03 US US10/506,223 patent/US7771727B2/en not_active Expired - Fee Related
- 2003-03-03 KR KR1020047013597A patent/KR101003622B1/ko not_active Expired - Fee Related
- 2003-03-03 CN CNA038099276A patent/CN1649625A/zh active Pending
- 2003-03-03 BR BRPI0308090-0A patent/BR0308090A/pt not_active IP Right Cessation
- 2003-03-03 CA CA002476182A patent/CA2476182A1/en not_active Abandoned
- 2003-03-03 CN CN2010106215969A patent/CN102133407A/zh active Pending
- 2003-03-03 EP EP03716299A patent/EP1487493B1/en not_active Expired - Lifetime
- 2003-03-03 AT AT03716299T patent/ATE455561T1/de active
- 2003-03-03 IL IL16357303A patent/IL163573A0/xx unknown
- 2003-03-03 NZ NZ534719A patent/NZ534719A/en not_active IP Right Cessation
- 2003-03-03 DK DK03716299.7T patent/DK1487493T3/da active
- 2003-03-03 MX MXPA04008419A patent/MXPA04008419A/es active IP Right Grant
- 2003-03-03 WO PCT/US2003/006657 patent/WO2003074551A2/en not_active Ceased
- 2003-03-03 ES ES03716299T patent/ES2339934T3/es not_active Expired - Lifetime
- 2003-03-03 DE DE60331049T patent/DE60331049D1/de not_active Expired - Lifetime
- 2003-03-03 AU AU2003220011A patent/AU2003220011B2/en not_active Ceased
- 2003-03-03 JP JP2003573017A patent/JP4477881B2/ja not_active Expired - Lifetime
- 2003-03-03 PL PL03373567A patent/PL373567A1/xx not_active Application Discontinuation
-
2004
- 2004-08-19 ZA ZA200406614A patent/ZA200406614B/en unknown
- 2004-08-31 IS IS7431A patent/IS7431A/is unknown
- 2004-09-24 NO NO20044039A patent/NO20044039L/no not_active Application Discontinuation
- 2004-09-29 CO CO04097209A patent/CO5611160A2/es not_active Application Discontinuation
-
2009
- 2009-08-25 US US12/547,096 patent/US20090324620A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060009622A1 (en) | 2006-01-12 |
| CA2476182A1 (en) | 2003-09-12 |
| NZ534719A (en) | 2008-02-29 |
| EP1487493B1 (en) | 2010-01-20 |
| AU2003220011B2 (en) | 2008-05-29 |
| US7771727B2 (en) | 2010-08-10 |
| ATE455561T1 (de) | 2010-02-15 |
| PL373567A1 (en) | 2005-09-05 |
| DK1487493T3 (da) | 2010-05-25 |
| JP2006510571A (ja) | 2006-03-30 |
| EP1487493A2 (en) | 2004-12-22 |
| WO2003074551A8 (en) | 2005-11-03 |
| KR20040088568A (ko) | 2004-10-16 |
| ZA200406614B (en) | 2006-06-28 |
| MXPA04008419A (es) | 2004-11-26 |
| CO5611160A2 (es) | 2006-02-28 |
| ES2339934T3 (es) | 2010-05-27 |
| CN1649625A (zh) | 2005-08-03 |
| JP4477881B2 (ja) | 2010-06-09 |
| WO2003074551A3 (en) | 2004-03-25 |
| NO20044039L (no) | 2004-09-29 |
| WO2003074551A2 (en) | 2003-09-12 |
| EP1487493A4 (en) | 2006-08-30 |
| DE60331049D1 (de) | 2010-03-11 |
| US20090324620A1 (en) | 2009-12-31 |
| BR0308090A (pt) | 2006-04-11 |
| CN102133407A (zh) | 2011-07-27 |
| IL163573A0 (en) | 2005-12-18 |
| KR101003622B1 (ko) | 2010-12-24 |
| AU2003220011A1 (en) | 2003-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7431A (is) | Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða | |
| DE60239707D1 (de) | Antimikrobielle kationische peptide und diese enthaltende formulierungen | |
| CY1109119T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη | |
| CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
| CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
| CY1109972T1 (el) | Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας | |
| HUP0300590A2 (hu) | Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| BR0107691A (pt) | Sapogeninas substituìdas e seu uso | |
| CY1112738T1 (el) | Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη | |
| CY1105225T1 (el) | Παραγωγα 5-β-σαπωγενινης και ψευδοσαπωγενινης και η χρηση τους στην αντιμετωπιση ανοιας | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| SE9904377D0 (sv) | Pharmaceutical combinations | |
| SG149872A1 (en) | Antagonists of the bradykinin b1 receptor | |
| NO20055838L (no) | Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav | |
| BRPI0417265A (pt) | composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| DK1372665T3 (da) | Hormonerstatningsbehandling og administration | |
| ATE456573T1 (de) | Nmb0928-protein und dessen verwendung in pharmazeutischen formulierungen | |
| HK1073999A (en) | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |